MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Legal costs push C.R. Bard to Q2 red

Legal costs push C.R. Bard to Q2 red

By

C.R. Bard (NYSE:BCR) shares dipped a bit today after the device maker posted a 2nd-quarter swing to red ink on $292.4 million in product liability charges.

The Murray Hill, N.J.-based medical device company reported higher-than-expected sales on strong performances from its oncology and surgical divisions, but swung from black to red ink in Q2. Bard posted losses of $161.6 million, or $2.03 per share, on sales of $759.9 million during the 3 months ended June 30, with top-line growth of 2.3%.

Adjusted to exclude the legal charges and other 1-time items, earnings per share reached $1.42, 4¢ ahead of expectations on Wall Street but 20¢ less than reported for the same period in 2012.

CFO Christopher Holland said the listed litigation charges are Bard’s best guess at its total liability for the Avaulta pelvic mesh lawsuits, both existing and pending

"There’s certainly not a way for us to say with absolute certainty that this is the final number," Holland told analysts during a conference call. "These products were all manufactured outside the U.S., and so to the extent there’s a cash – ultimately a cash outlay, we’ll be able to utilize our [outside-the-U.S.] cash balance."

"These adjusted results exceeded the guidance we provided for the quarter. Our investment plan is proceeding as planned, and our teams are executing on the opportunities in front of us," CEO Timothy Ring added.

BCR shares were trading at $112.04 apiece as of about 3:05 p.m. today, down 1.2%.

Wall Street has been optimistic on the medical device maker after Bard won a patent infringement lawsuit with W.L. Gore & Assoc., with the proceeds from the suit expected to pay out in Q3 and beyond.

On July 10, a Avaulta personal injury suit ended in a mistrial after a witness blurted comments about Bard’s marketing while on the stand. The judge had banned any reference to the decision to pull the vaginal mesh off the market, leading Bard’s lawyers to ask for a mistrial. A new jury trial is slated for later this month.

In case you missed it

RSS From Medical Design & Outsourcing

  • iRhythm plans silent AFib screening pilots, high-level hires and Zio Watch evaluations
    iRhythm Technologies (NSDQ:IRTC) has big plans for 2022 and its remote external electrocardiogram monitors as the medical device developer gears up for growth. President and CEO Quentin Blackford is looking to hire an international general manager among other roles in the coming months, he told Medical Design & Outsourcing after presenting at this month’s 2022… […]
  • Innophase announces next-gen low-power WiFi modules
    Innophase (San Diego) recently announced its next-generation Talaria Two INP1014 and INP1015 WiFi plus BLE5 modules. The new modules are 40% smaller than the previous INP1010 and INP1011 platforms. INP1014 and INP1015 can enable edge-of-network IoT devices, including medical wearables, that require low power consumption and a direct-to-cloud connection, according to the company. The platforms… […]
  • Plastics and medical devices: Changes for safety and cost
    The move toward polypropylene and polyethylene in medical devices requires new manufacturing and assembly solutions such as ultrasonic and laser welding. Didier Perret, Emerson Plastics are ubiquitous in medical applications thanks to their light weight, durability and flexibility, among other attributes. However, concern has been increasing in recent years about the possible negative effects of… […]
  • Medtronic’s recall of HawkOne system is Class I
    The FDA today issued a notice confirming that the recall of Medtronic’s (NYSE:MDT) HawkOne system is Class I, the most serious kind. So far in 2022, the FDA has classified three Medtronic-related recalls as Class I, with the Covidien (part of Medtronic) Puritan Bennett 980 series ventilator and the Synergy Cranial and StealthStation S7 Cranial software receiving the same classification earlier… […]
  • January 2022 Issue: The pandemic tested Metronic’s mettle
      The pandemic tested Medtronic’s mettle: Its CFO explains how How Abbott seeks to improve care, health inequities for people with cardiovascular disease Medtech’s biggest personnel changes in 2021 The top 5 medtech news stories of 2021 Some thoughts for medtech leaders in 2022 Starting our third year of the COVID-19 pandemic, I wonder when… […]
  • Feinstein Institutes researchers develop tiny implantable neurostimulator for mouse studies
    Researchers have developed a novel, fully implantable wireless bidirectional vagus nerve stimulation (VNS) and sensing device for mice. Engineers and researchers at the Institute of Bioelectronic Medicine at The Feinstein Institutes for Medical Research published details about the device and its capabilities in Biosensors and Bioelectronics. They think the device has the potential to transform how… […]
  • MIT team working on all-in-one diabetes management devices
    MIT researchers are touting a platform aimed at helping patients maintain healthy glucose levels by streamlining the diabetes management process. The MIT researchers say it’s hard for people with diabetes to maintain a treatment regimen. Typically at every meal, they need to estimate carbohydrate content, draw blood to measure blood glucose levels, and calculate the… […]
  • Element expands life sciences testing business with pharma, biotech capabilities
    Element Materials Technology recently announced that with the completed acquisition of JMI Laboratories in 2021, it has built out its life sciences testing capabilities for the pharmaceutical and biopharmaceutical industries. The acquisition added more than 1,000 experts in 23 facilities in North America and Europe and marked a strategic shift for the London-based company to… […]
  • Team Technologies acquires consumable medical device manufacturer iiMed
    Team Technologies recently announced that it acquired consumable medical device manufacturer iiMed Medical Solutions for an undisclosed amount. The acquisition is the fourth purchase since Clearlake Capital Group invested in the company in 2018. It is the eighth transaction completed by the company since 2012. Nearshore specialty manufacturer iiMed makes FDA Class I and Class… […]
  • P-Duke Technology is selling dc/dc converters for medical
    P-Duke Technology is promoting its MPS and MPH series of medical dc/dc converters. The MPS and MPH series comply with Medical EN60601-1 and I.T.E. EN 62368-1 certifications, according to the company. They provide 2W and 3.5W output power, 2:1 input range, regulated 5, 9, 12, 15, 24, ±12, ±15 VDC output voltage, and both DIP16… […]
  • Philips backing efforts to reduce CIED infections
    Royal Philips (NYSE:PHG) announced today that it supports the American Heart Association’s efforts to reduce CIED infections. Amsterdam-based Philips offered its support to the initiative to generate awareness among cross-disciplinary specialties and improve survival rates from CIED (cardiovascular implantable electronic device) infections. The company said in a news release that, with its support, the American… […]

Leave a Reply